Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Choosing between tucatinib and T-DXd in HER2+ breast cancer

Wolfgang Janni • 22 Sep 2021
ESMO 2021
Breast Cancer Antibodies Trastuzumab deruxtecan Tucatinib
DESTINY-Breast03 HER2CLIMB

The therapeutic landscape for patients with HER2-positive breast cancer has dramatically changed in recent years. Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany, contexualises the results of the DESTINY-Breast03 study demonstrating the superiority of trastuzumab deruxtecan (T-DXd) in HER2-positive breast cancer alongside the findings from the HER2CLIMB study evaluating tucatinib in patients with HER2-positive breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

More from Wolfgang Janni

1:46
SUCCESS-A trial: ctDNA screening's potential in early-stage breast cancer recurrence prediction
Wolfgang Janni • 5 Dec 2023
1:37
SURVIVE study: liquid biopsy guided follow-up surveillance in early breast cancer
Wolfgang Janni • 5 Dec 2023
1:36
ctDNA assay for detection of recurrent disease in patients with early-stage breast cancer
Wolfgang Janni • 22 Sep 2021
1:19
MONALEESA-2: improved OS seen in HR+ advanced breast cancer treated with ribociclib + letrozole
Wolfgang Janni • 22 Sep 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals